The acquisition is the next step in Comar’s strategic plan, beginning with the divestiture of its glass vial product line, and focuses on organic growth and acquisitions within plastic pharmaceutical and medical packaging. The transaction includes the leased real estate, manufacturing equipment, plant operations, management and employees.
Unicon’s primary end market is pharmaceutical packaging serving a list of customers including pharmaceutical companies, contract packagers, and distributors.
Comar believes that the operations, product line and customer base are a strong fit with the company, and manufacturing at Unicon’s facility will continue and will be expanded. The company boasts of good market presence in the Liquid Medication Delivery Device Market.
Mike Ruggieri, president of Comar, said: “Unicon’s products, production capabilities, and facility will complement and enhance Comar’s existing product lines and position the combined entity for future growth. Unicon is a perfect fit for our business. We are excited to welcome Unicon’s staff and customers to the Comar family.
“This acquisition gives our business a high quality, redundant facility for production while also expanding our capacity to keep up with our rapid organic growth. Unicon’s and Comar’s customer base will benefit from the choices offered by our combined, expanded product line.”
P&M Corporate Finance served as exclusive financial advisor to Comar and assisted in the development and execution of Comar’s acquisition growth strategy.
Currently, Comar services the pharmaceutical, biotech, diagnostic, ophthalmic, healthcare, personal care, and retail pharmacy markets. Product line includes multiple patents for its line of oral dispensers, dosage cups, dropper assemblies, closures, and other primary packaging products.